Minireviews
Copyright ©The Author(s) 2022.
World J Gastroenterol. Jul 21, 2022; 28(27): 3398-3409
Published online Jul 21, 2022. doi: 10.3748/wjg.v28.i27.3398
Table 1 Studies using artificial intelligence based on ultrasound for fatty liver disease diagnosis
Task
Reference standard
Sample size
Method
Results
Ref.
Fatty liver disease diagnosisLiver biopsy55 patients with severe obesity, 38 of whom had fatty liver diseaseDeep learning with B-mode image ultrasoundSensitivity: 100%; specificity: 88%; accuracy: 96%; AUC: 0.98[26]
Fatty liver disease diagnosisRadiologist qualitative score157 ultrasound liver images from unknown number of participantsDeep learning with B-mode image ultrasound Sensitivity: 95%; specificity: 85%; accuracy: 90.6%; AUC: 0.96[28]
NAFLD assessmentMRI proton density fat fraction204 participants, 140 of whom had NAFLD, 64 control participants One-dimensional CNNsSensitivity: 97%; specificity: 94%; accuracy: 96%; AUC: 0.98[31]
NAFLD assessmentMRI proton density fat fraction135 adult participants with known or suspected NAFLD Transfer learning with a pretrained CNN by four ultrasound views of liver routinely obtainedSCC: 0.81; AUC: 0.91 (PDFF ≥ 5%)[27]
NAFLD assessmentLiver biopsy295 subjects, 198 mild fatty liver, one moderate degree of fatty liverDCNN-based organ segmentation with Gaussian mixture modeling for automated quantification of the HRIICC of two radiologists and DCNN were 0.919, 0.916, 0.734[33]
The severity of fatty liverAbdominal ultrasound21855 B-mode ultrasound images, 2070 patients with different severities from none to severe fatty liverPretrained CNN models with B-mode ultrasound imagesThe areas under the receiver operating characteristic curves were 0.974 (mild steatosis vs others), 0.971 (moderate steatosis vs others), 0.981 (severe steatosis vs others), 0.985 (any severity vs normal) and 0.996 (moderate-to-severe steatosis clinically abnormal vs normal-to-mild steatosis clinically normal)[29]
Table 2 Studies using artificial intelligence based on ultrasound for focal liver lesion diagnosis
Modality and task
Approach
Target disease: number of the case
Performance
Ref.
Classifying different FLLs based on B-modeANNCyst: 29; hemangioma: 37; malignant tumor: 33Cyst vs hemangioma accuracy: 99.7%; cyst vs malignant tumor accuracy: 98.7%; hemangioma vs malignant tumor accuracy: 96.1%[40]
Differentiating benign and malignant lesions based on B-modeCNNBenign lesions: 300; malignant lesions: 296All lesion accuracy: 84%; uncertain set of lesion accuracy: 79%[37]
Classifying different FLLs based on B-modeANN (sparse autoencoder)Normal liver: 16; cyst: 44; hemangioma: 18; HCC: 30overall accuracy: 97.2%; overall sensitivity: 98%; overall specificity: 95.7%[41]
Differentiating benign and malignant lesions based on B-modeFSVMtraining set; DS1: benign lesions: 132, malignant lesions: 68; DS2: malignant liver cancer: 50, hepatocellular adenoma: 150, hemangioma: 35, focal nodular hyperplasia: 145, lipoma: 70DS1: accuracy: 97%, sensitivity: 100%, specificity: 95.5%, AUC: 0.984; DS2: accuracy: 95.1%, sensitivity: 92.0%, specificity: 95.5%, AUC: 0.971[36]
Classifying different FLLs based on B-modeCNNNon-tumorous liver: 258, hemangioma: 17, HCC: 6, cyst: 30, focal nodular hyperplasia: 8AUC for tumor detection: 0.935; AUC for tumor discrimination (mean): 0.916[42]
Diagnosing HCC based on B-mode CNNMalignant tumor: 1786; benign tumor: 427AUC for EV: 0.924[38]
Differentiating benign and malignant lesions based on B-modeCNNHCC: 6; cyst: 6600; hemangioma: 5374; focal fatty sparing: 5110; focal fatty infiltration: 934IV: overall sensitivity: 83.9%; overall specificity: 97.1%; HCC detection rate: 85.3%; EV: overall sensitivity: 84.9%; overall specificity: 97.1%; HCC detection rate: 78.3%[39]
Classifying different FLLs based on CEUSANNhemangioma: 16; focal fatty liver: 23; HCC: 41; metastatic tumor: 32 (hypervascular: 20 hypovascular: 12)Accuracy: 94.5%; sensitivity: 93.2%; specificity: 89.7%[47]
Differentiating benign and malignant lesions based on CEUSDeep belief networksHCC: 6; hemangioma: 10; liver abscess: 4; metastases: 3; focal fatty sparing: 3Accuracy: 83.4%; sensitivity: 83.3%; specificity: 87.5%[59]
Differentiating benign and malignant lesions based on CEUSSVMBenign tumor: 30; malignant tumor: 22Accuracy: 90.3%; sensitivity: 93.1%; specificity: 86.9%[45]
Differentiating benign and malignant lesions based on CEUSSVMBenign tumor, HCC or metastatic tumor: 98Benign vs malignant accuracy: 91.8%, sensitivity: 93.1%, specificity: 86.9%; benign vs HCC vs metastatic carcinoma: accuracy: 85.7%; sensitivity: 84.4%; specificity: 87.7%[46]
Differentiating benign and malignant lesions based on CEUSDeep canonical correlation analysis + multiple kernel learningBenign tumor: 46; malignant tumor: 47Accuracy: 90.4%; sensitivity: 93.6%; specificity: 86.9%[43]
Differentiating benign and malignant lesions based on CEUS3D-CNNHCC: 2110; focal nodular hyperplasia: 2310Accuracy: 93.1%; sensitivity: 94.5%; specificity: 93.6%[44]
Differentiating benign and malignant lesions based on CEUSDeep neural network Focal nodular hyperplasia: 16; HCC: 30; hemangioma: 23; hypervascular metastasis: 11; hypovascular metastasis: 11Top accuracy: 88%[48]
Differentiating benign and malignant lesions based on CEUSCNNDevelopment set: malignant tumor: 281, benign tumor: 82; testing set: malignant tumor: 164, benign tumor: 47Accuracy: 91.0%; sensitivity: 92.7%; specificity: 85.1%; AUC: 0.934[49]